Multi-centre, randomised, open-label, blinded endpoint assessed, trial of corticosteroids plus intravenous immunoglobulin (IVIG) and aspirin, versus IVIG and aspirin for prevention of coronary artery aneurysms in Kawasaki disease.

KD-CAAP is a multi-centre, randomised trial of corticosteroids plus standard of care treatment versus standard of care treatment alone to prevent heart complications in Kawasaki disease. The trial is sponsored by University College London and is managed by the Medical Research Council (MRC) Clinical Trials Unit (KD-CAAP Co-ordinating Centre).

The standard treatment for Kawasaki disease is Intravenous immunoglobulin (IVIG) and aspirin, used to “dampen down” inflammatory processes which occur in the first few days of the illness, but many children and adolescents still develop significant heart damage despite IVIG.

KD-CAAP will tell us whether giving corticosteroids upfront (in addition to IVIG and aspirin) to children and adolescents with Kawasaki disease reduces the high rate of heart complications.